20260424_PYFA_Ringkasan Risalah//Risalah RUPS_32073364_lamp2.pdf

D.   The Meeting was attended by 7.869.867.725 (seven billion eight hundred sixty nine million
     eight hundred sixty seven thousand seven hundred and twenty five) shares with valid voting
     rights, representing 70,04% (seventy point four percent) of the total 11.236.694.464 (eleven
     billion two hundred thirty six million six hundred ninety four thousand four hundred sixty
     four) shares, being all shares with valid voting rights issued by the Company.

E. In the Meeting, each Shareholder/proxy was given the opportunity to ask questions and/or provide
   opinions, related to each Meeting agenda.

F. The decision-making mechanism in the Meeting is as follows:
   Meeting decisions were made by way of deliberation to reach consensus, if there were
   shareholders or their proxies who vote against or abstain, voting would be made electronically
   through eASY.KSEI or physically (by way of show of hand for those against).

G. The number of shareholders or its proxy who asked questions and/or provided opinions as well
   as the results of the voting on the agenda of the Meeting is as follows :


                         The number of                               Voting Results
                      Shareholders/Proxies
         Meeting
                      who asked questions
         Agenda                                        Affirmative           Dissenting     Abstain
                         and/or provide
                           opinions
                                                  7,869,238,725 shares        557.500        71,500
             1                   1                  (99.99% of those           shares        shares
                                                        present)              (0.01%)       (0.006%)
                                                  7,869,238,725shares                        71,500
             2                   0                  (99.99% of those             0           shares
                                                        present)                            (0.006%)


H.   Whereas in the Company’s Meeting the following decisions have been made with unanimous
     votes:

     Meeting Agenda 1:

     1. Approval for the implementation of the Capital Increase with Pre-emptive Rights II in 2026 (the
        “PMHMETD II”) pursuant to Financial Services Authority Regulation No. 32/POJK.04/2015
        regarding Capital Increase of Public Companies with Pre-emptive Rights, as amended by
        Financial Services Authority Regulation No. 14/POJK.04/2019, through the issuance of new
        shares of the Company in a maximum amount of 5,700,000,000 (five billion seven hundred
        million) shares, with a nominal value of IDR 100 (one hundred Rupiah) per share, which will be
        accompanied by the issuance of warrants attached to the shares issued from the
        implementation of the PMHMETD II, in accordance with the prevailing laws and regulations,
        including capital market regulations;
     2. Approval to authorize the Company's Board of Directors to undertake all necessary actions
        regarding with PMHMETD II, in compliance with the conditions stipulated in the prevailing laws
        and regulations, including capital market regulations, including but not limited to:
         a. Determining all conditions and provisions for the implementation of PMHMETD II, including
              but not limited to the certainty of the number of shares issued in the context of PMHMETD
              II, and the exercise price in the context of PMHMETD II;
         b. Signing the necessary documents, including notarial deeds and registration statement
              documents to the Financial Services Authority (OJK);
         c. Determining the Record Date (List of Shareholders) for entitlement to PMHMETD II;
         d. Setting the schedule for PMHMETD II;
         e. Establishing the ratios of shareholders entitled to PMHHMETD II;
         f. Ensuring the use of funds from the proceeds of PMHMETD II;

    g. Determining standby buyers (if there are any), as well as specifying the terms and
       conditions and signing all deeds and/or agreements and/or documents between the
       Company and standby buyers.

Meeting Agenda 2:

1. Approval for the amendment to Article 4 paragraph (2) of the Company’s Articles of Association
   in connection with the increase in the Company’s issued and paid-up capital in relation to the
   implementation of the Company’s PMHMETD II, which will also be accompanied by the
   issuance of warrants attached to the shares issued from the implementation of the PMHMETD
   II;
2. In connection with the amendment of Article 4 paragraph 2 of the Company's Articles of
   Association, approval is granted to authorize the Company's Board of Directors (with
   substitution rights) to declare the increase in subscribed and paid-up capital, specifically the
   amendment to Article 4 paragraph 2 of the Company's Articles of Association after the
   completion of PMHMETD II. Subsequently, the Board is empowered to submit a notification of
   the amendment to the Company's Articles of Association to the Minister of Law and Human
   Rights of the Republic of Indonesia. This includes making any changes and/or additions in any
   form deemed necessary for the aforementioned purpose, submitting and signing all other
   applications and documents, and executing any other actions that may be required.

                                  Jakarta, April 24th 2026
                        The Board of Directors PT Pyridam Farma Tbk.